Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Levis

Showing results (81-90 of 135) with videos related to

Pageof 14
Sort By:
Blood Cancer Journal|May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenibAlexander E Perl, Naoko Hosono, Pau Montesinos, et al.
NPJ Precision Oncology|May 15, 2021
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic featuresJohn-William Sidhom, Ingharan J Siddarthan, Bo-Shiun Lai, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Leukemia Research|July 1, 2019
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia inductionBryan C Hambley, Kelly J Norsworthy, Jagar Jasem, et al.
Blood|January 18, 2011
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemiasJudith E Karp, B Douglas Smith, Linda S Resar, et al.
Leukemia Research|September 5, 2017
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literatureKelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, et al.
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Haematologica|April 1, 2026
<i>Erratum</i> to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial"Richard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Pageof 14

Showing results (81-90 of 135) with videos related to

Sort By:
Pageof 14
Blood Cancer Journal|May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenibAlexander E Perl, Naoko Hosono, Pau Montesinos, et al.
NPJ Precision Oncology|May 15, 2021
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic featuresJohn-William Sidhom, Ingharan J Siddarthan, Bo-Shiun Lai, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Leukemia Research|July 1, 2019
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia inductionBryan C Hambley, Kelly J Norsworthy, Jagar Jasem, et al.
Blood|January 18, 2011
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemiasJudith E Karp, B Douglas Smith, Linda S Resar, et al.
Leukemia Research|September 5, 2017
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literatureKelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, et al.
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Haematologica|April 1, 2026
<i>Erratum</i> to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial"Richard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Pageof 14